Pfizer Shake Up Continues With Key Exits From Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
In the wake of CEO Jeff Kindler's abrupt departure earlier this week, Pfizer has announced two key departures from its emerging markets team, suggesting greater changes may be on the way at the world's largest drug maker
You may also be interested in...
Life After Pfizer: MicuRx Forms JV To Develop Antibiotics In China
The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.
Pfizer On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 2 of 2)
On the way back to his old job in the U.S., after a stint in Shanghai as head of research in Asia, VP Richard Connell, head of Preclinical Outsourcing says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.
Pfizer Head of Preclinical Outsourcing VP Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 1 of 2)
On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.